See more : Mahindra & Mahindra Limited (MHID.IL) Income Statement Analysis – Financial Results
Complete financial analysis of Novo Nordisk A/S (NVO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Novo Nordisk A/S, a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Nubian Resources Ltd. (NBR.V) Income Statement Analysis – Financial Results
- Ramelius Resources Limited (RMLRF) Income Statement Analysis – Financial Results
- Kenmare Resources plc (KMR.IR) Income Statement Analysis – Financial Results
- Fission 3.0 Corp. (FISOF) Income Statement Analysis – Financial Results
- DATA Communications Management Corp. (DCMDF) Income Statement Analysis – Financial Results
Novo Nordisk A/S (NVO)
About Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Gilead Sciences, Inc. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 | 1994 | 1993 | 1992 | 1991 | 1990 | 1989 | 1988 | 1987 | 1986 | 1985 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 232.26B | 176.95B | 140.80B | 126.95B | 122.02B | 111.83B | 111.70B | 111.78B | 107.93B | 88.81B | 83.57B | 78.03B | 66.35B | 60.78B | 51.08B | 45.67B | 41.89B | 38.75B | 33.71B | 29.23B | 26.61B | 25.15B | 23.72B | 20.82B | 20.94B | 17.91B | 16.98B | 14.90B | 13.71B | 13.52B | 13.15B | 10.67B | 9.83B | 8.33B | 7.62B | 5.63B | 5.03B | 4.19B | 4.16B |
| Cost of Revenue | 35.77B | 28.45B | 23.66B | 20.93B | 20.09B | 17.62B | 17.63B | 17.18B | 16.19B | 14.56B | 14.14B | 13.47B | 12.59B | 11.68B | 10.44B | 10.13B | 9.80B | 9.59B | 9.17B | 8.11B | 7.46B | 6.62B | 5.96B | 4.38B | 5.05B | 4.39B | 4.72B | 4.17B | 3.83B | 3.83B | 6.41B | 2.53B | 4.80B | 4.13B | 3.76B | 2.72B | 2.59B | 3.29B | 2.07B |
| Gross Profit | 196.50B | 148.51B | 117.14B | 106.01B | 101.93B | 94.21B | 94.06B | 94.60B | 91.74B | 74.24B | 69.43B | 64.56B | 53.76B | 49.10B | 40.64B | 35.53B | 32.09B | 29.16B | 24.55B | 21.13B | 19.15B | 18.53B | 17.75B | 16.44B | 15.89B | 13.52B | 12.26B | 10.74B | 9.88B | 9.68B | 6.74B | 8.14B | 5.03B | 4.21B | 3.85B | 2.91B | 2.44B | 893.58M | 2.09B |
| Gross Profit Ratio | 84.60% | 83.92% | 83.20% | 83.51% | 83.54% | 84.25% | 84.21% | 84.63% | 85.00% | 83.60% | 83.08% | 82.74% | 81.03% | 80.78% | 79.56% | 77.81% | 76.60% | 75.26% | 72.81% | 72.27% | 71.96% | 73.66% | 74.85% | 78.96% | 75.89% | 75.50% | 72.20% | 72.04% | 72.07% | 71.64% | 51.26% | 76.32% | 51.22% | 50.49% | 50.59% | 51.75% | 48.49% | 21.34% | 50.14% |
| Research & Development | 32.44B | 24.05B | 17.77B | 15.46B | 14.22B | 14.81B | 14.01B | 14.56B | 13.61B | 13.76B | 11.73B | 10.90B | 9.63B | 9.60B | 7.86B | 7.87B | 8.55B | 6.32B | 5.07B | 4.38B | 4.20B | 4.13B | 3.96B | 3.22B | 3.36B | 3.40B | 2.77B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 4.86B | 4.47B | 4.05B | 3.96B | 4.01B | 3.92B | 3.78B | 3.96B | 3.86B | 3.54B | 3.51B | 3.31B | 3.25B | 3.72B | 2.76B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 56.74B | 46.22B | 37.01B | 32.93B | 31.82B | 29.40B | 28.34B | 28.38B | 28.31B | 23.22B | 23.38B | 21.54B | 19.00B | 18.20B | 15.42B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 61.60B | 50.68B | 41.06B | 36.89B | 35.83B | 33.31B | 32.12B | 32.34B | 32.17B | 26.76B | 26.89B | 24.86B | 22.25B | 21.92B | 18.18B | 15.82B | 14.90B | 14.00B | 11.79B | 10.30B | 9.67B | 9.42B | 9.06B | 7.93B | 7.50B | 6.59B | 6.02B | 7.69B | 6.87B | 6.79B | 3.99B | 6.29B | 3.04B | 2.63B | 2.33B | 1.65B | 1.52B | 0.00 | 1.15B |
| Other Expenses | -119.00M | -1.03B | -332.00M | -460.00M | -600.00M | -1.15B | -1.04B | -737.00M | -3.48B | -770.00M | -682.00M | -666.00M | 0.00 | 0.00 | 0.00 | -572.36M | -322.18M | -271.23M | -397.15M | -581.71M | -1.12B | -997.95M | -860.46M | 1.03B | 1.43B | 1.47B | 1.14B | 1.07B | 1.14B | 1.06B | 799.09M | 693.74M | 591.94M | 520.42M | 471.78M | 323.77M | 266.42M | 224.68M | 199.90M |
| Operating Expenses | 93.92B | 73.70B | 58.50B | 51.89B | 49.45B | 46.97B | 45.10B | 46.17B | 42.30B | 39.75B | 37.94B | 35.09B | 31.88B | 31.52B | 26.05B | 23.12B | 23.13B | 20.04B | 16.47B | 14.10B | 12.75B | 12.56B | 12.16B | 12.19B | 12.28B | 11.46B | 9.93B | 8.76B | 8.01B | 7.84B | 4.79B | 6.99B | 3.63B | 3.15B | 2.80B | 1.98B | 1.79B | 224.68M | 1.35B |
| Cost & Expenses | 129.69B | 102.15B | 82.16B | 72.82B | 69.54B | 64.58B | 62.73B | 63.35B | 58.48B | 54.31B | 52.08B | 48.55B | 44.47B | 43.20B | 36.49B | 33.26B | 32.93B | 29.63B | 25.64B | 22.20B | 20.22B | 19.18B | 18.12B | 16.57B | 17.33B | 15.84B | 14.65B | 12.92B | 11.84B | 11.68B | 11.20B | 9.51B | 8.43B | 7.28B | 6.57B | 4.69B | 4.38B | 3.52B | 3.43B |
| Interest Income | 1.07B | 239.00M | 2.89B | 337.00M | 65.00M | 51.00M | 69.00M | 52.00M | 85.00M | 167.00M | 56.00M | 125.00M | 514.00M | 382.00M | 375.00M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 739.00M | 378.00M | 2.45B | 390.00M | 220.00M | 85.00M | 90.00M | 65.00M | 6.05B | 563.00M | 55.00M | 1.79B | 959.00M | 2.06B | 1.27B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 9.41B | 6.60B | 5.31B | 5.28B | 4.68B | 3.81B | 2.87B | 2.65B | 3.04B | 3.60B | 3.57B | 2.82B | 20.00M | 2.85B | 3.27B | 2.08B | 1.90B | 1.64B | 1.21B | 1.44B | 1.63B | 1.33B | 208.85M | 665.76M | 1.19B | 1.47B | 1.14B | 1.07B | 1.14B | 1.06B | 799.09M | 693.74M | 591.94M | 520.42M | 471.78M | 323.77M | 266.42M | 224.68M | 199.90M |
| EBITDA | 113.33B | 76.41B | 64.83B | 58.57B | 56.31B | 51.57B | 51.69B | 50.58B | 49.58B | 38.09B | 35.25B | 30.44B | 24.94B | 21.25B | 17.80B | 14.48B | 11.97B | 10.76B | 9.29B | 8.47B | 8.02B | 6.05B | 5.81B | 4.91B | 4.81B | 2.09B | 2.31B | 2.15B | 2.61B | 2.42B | 2.26B | 812.29M | 1.54B | 1.19B | 1.27B | 1.02B | 708.41M | 675.51M | 673.20M |
| EBITDA Ratio | 48.79% | 46.36% | 47.98% | 47.43% | 47.36% | 45.75% | 46.70% | 46.18% | 48.63% | 42.90% | 41.95% | 41.39% | 33.75% | 35.77% | 35.63% | 31.71% | 25.91% | 27.76% | 27.54% | 28.98% | 22.57% | 24.06% | 24.48% | 23.58% | 22.94% | 11.68% | 13.59% | 14.45% | 19.05% | 17.91% | 17.22% | 7.61% | 15.70% | 14.23% | 16.61% | 18.05% | 14.09% | 16.13% | 16.19% |
| Operating Income | 102.57B | 74.81B | 58.64B | 54.13B | 52.48B | 47.25B | 48.97B | 48.43B | 49.44B | 34.49B | 31.49B | 29.47B | 22.37B | 18.89B | 14.93B | 12.40B | 8.95B | 9.12B | 8.08B | 7.03B | 4.38B | 4.72B | 5.60B | 4.24B | 3.62B | 623.53M | 1.17B | 1.09B | 1.47B | 1.37B | 1.47B | 118.55M | 950.89M | 664.82M | 793.56M | 692.21M | 442.00M | 450.83M | 473.30M |
| Operating Income Ratio | 44.16% | 42.28% | 41.65% | 42.64% | 43.01% | 42.25% | 43.84% | 43.33% | 45.81% | 38.84% | 37.68% | 37.77% | 33.72% | 31.08% | 29.24% | 27.16% | 21.38% | 23.53% | 23.95% | 24.05% | 16.46% | 18.77% | 23.60% | 20.39% | 17.26% | 3.48% | 6.86% | 7.29% | 10.74% | 10.10% | 11.14% | 1.11% | 9.67% | 7.98% | 10.42% | 12.30% | 8.79% | 10.77% | 11.38% |
| Total Other Income/Expenses | 2.10B | -5.75B | 436.00M | -996.00M | -3.93B | 367.00M | -287.00M | -634.00M | -5.96B | -396.00M | 1.05B | -1.66B | -449.00M | -605.00M | -945.00M | 320.95M | 2.03B | 45.20M | 144.99M | 477.44M | 1.18B | 1.57B | 417.70M | 601.59M | 340.08M | 3.12B | 2.01B | 1.44B | 681.11M | 565.52M | 407.02M | 1.55B | 511.52M | 473.05M | 255.71M | 213.09M | 255.44M | 337.76M | 403.38M |
| Income Before Tax | 104.67B | 69.06B | 59.08B | 53.13B | 48.55B | 47.62B | 48.68B | 47.80B | 43.48B | 34.10B | 32.54B | 27.81B | 21.93B | 18.29B | 13.99B | 12.73B | 10.98B | 9.17B | 8.22B | 7.51B | 7.58B | 6.29B | 6.01B | 4.84B | 3.96B | 3.75B | 3.17B | 2.53B | 2.15B | 1.93B | 1.87B | 1.67B | 1.46B | 1.14B | 1.05B | 905.31M | 697.44M | 788.58M | 876.68M |
| Income Before Tax Ratio | 45.07% | 39.03% | 41.96% | 41.85% | 39.79% | 42.58% | 43.58% | 42.76% | 40.29% | 38.39% | 38.94% | 35.64% | 33.05% | 30.09% | 27.39% | 27.87% | 26.22% | 23.65% | 24.38% | 25.68% | 28.48% | 25.01% | 25.36% | 23.28% | 18.88% | 20.91% | 18.67% | 16.97% | 15.71% | 14.29% | 14.24% | 15.68% | 14.88% | 13.66% | 13.77% | 16.08% | 13.87% | 18.83% | 21.08% |
| Income Tax Expense | 20.99B | 13.54B | 11.32B | 10.99B | 9.60B | 8.99B | 10.55B | 9.87B | 8.62B | 7.62B | 7.36B | 6.38B | 4.83B | 3.88B | 3.22B | 3.06B | 2.45B | 2.71B | 2.36B | 2.46B | 2.53B | 2.20B | 2.16B | 1.76B | 1.55B | 1.34B | 952.42M | 726.73M | 592.44M | 499.85M | 441.68M | 400.19M | 532.22M | 377.75M | 303.28M | 267.40M | 217.04M | 267.27M | 268.92M |
| Net Income | 83.68B | 55.53B | 47.76B | 42.14B | 38.95B | 38.63B | 38.13B | 37.93B | 34.86B | 26.48B | 25.18B | 21.43B | 17.10B | 14.40B | 10.77B | 9.67B | 8.54B | 6.45B | 5.86B | 5.05B | 4.87B | 4.09B | 3.85B | 3.09B | 2.41B | 2.41B | 2.22B | 1.80B | 1.56B | 1.43B | 1.43B | 1.27B | 930.19M | 760.12M | 745.99M | 637.91M | 480.40M | 521.32M | 607.76M |
| Net Income Ratio | 36.03% | 31.38% | 33.92% | 33.19% | 31.92% | 34.54% | 34.14% | 33.93% | 32.30% | 29.82% | 30.13% | 27.47% | 25.77% | 23.70% | 21.08% | 21.17% | 20.38% | 16.65% | 17.37% | 17.27% | 18.31% | 16.26% | 16.24% | 14.84% | 11.51% | 13.45% | 13.07% | 12.09% | 11.39% | 10.59% | 10.88% | 11.93% | 9.46% | 9.12% | 9.79% | 11.33% | 9.55% | 12.45% | 14.62% |
| EPS | 9.34 | 12.26 | 10.40 | 9.03 | 4.10 | 3.99 | 7.71 | 7.50 | 6.78 | 5.05 | 4.70 | 7.82 | 3.03 | 2.48 | 1.80 | 1.57 | 1.36 | 1.01 | 0.89 | 0.75 | 0.72 | 0.59 | 0.56 | 0.45 | 0.35 | 0.26 | 0.30 | 0.24 | 0.21 | 0.19 | 0.19 | 0.17 | 0.16 | 0.12 | 0.10 | 0.13 | 0.10 | 0.11 | 0.12 |
| EPS Diluted | 9.31 | 12.22 | 10.37 | 9.01 | 4.10 | 3.99 | 7.70 | 7.48 | 6.76 | 5.04 | 4.68 | 7.77 | 3.00 | 2.46 | 1.78 | 1.55 | 1.35 | 1.00 | 0.89 | 0.75 | 0.71 | 0.59 | 0.56 | 0.45 | 0.34 | 0.26 | 0.30 | 0.24 | 0.21 | 0.19 | 0.19 | 0.17 | 0.16 | 0.12 | 0.10 | 0.13 | 0.10 | 0.11 | 0.12 |
| Weighted Avg Shares Out | 4.48B | 4.53B | 4.59B | 4.67B | 4.75B | 4.84B | 4.96B | 5.07B | 5.16B | 5.26B | 5.39B | 5.52B | 5.65B | 5.81B | 5.99B | 3.09B | 3.15B | 3.21B | 3.28B | 3.38B | 3.42B | 3.46B | 3.44B | 3.46B | 3.80B | 3.80B | 3.77B | 3.74B | 3.76B | 3.74B | 3.76B | 3.76B | 5.83B | 3.13B | 4.03B | 5.16B | 5.08B | 5.07B | 5.02B |
| Weighted Avg Shares Out (Dil) | 4.49B | 4.54B | 4.61B | 4.68B | 4.76B | 4.85B | 4.96B | 5.07B | 5.16B | 5.26B | 5.39B | 5.52B | 5.70B | 5.85B | 6.04B | 3.11B | 3.18B | 3.23B | 3.29B | 3.39B | 3.44B | 3.49B | 3.47B | 3.47B | 3.80B | 3.80B | 3.77B | 3.74B | 3.76B | 3.74B | 3.76B | 3.76B | 5.83B | 3.13B | 4.03B | 5.16B | 5.08B | 5.07B | 5.02B |
The Score: GM, Macy's, Novo Nordisk and More Stocks That Defined the Week
Here are some of the major companies whose stocks moved on the week's news.
Is Novo Nordisk Stock a Buy?
Few companies garner as much reliable attention as Novo Nordisk (NVO) does these days. With a bull market coinciding with a historic run of growth for the Danish pharmaceutical giant related to its GLP-1 drugs, it's no surprise that its...
Biotech funding has been an issue in the pharmaceutical industry, says Novo Holdings partner
Johan Hueffer, senior partner, principal investments at Novo Holdings, discusses investment in life sciences and his macro perspective.
LLY, NVO Stock Up as Biden Proposes Medicare Cover for Obesity Drugs
The Biden administration believes that including obesity drugs in Medicare coverage will reduce out-of-pocket costs for the drugs and make them affordable.
Canada approves Novo Nordisk's obesity drug to reduce risk of non-fatal heart attack
Canada's health regulator has approved Novo Nordisk's weight loss drug Wegovy to reduce the risk of nonfatal heart attack or myocardial infarction in some adults, the Danish drugmaker said on Wednesday.
Millions more Americans might get access to GLP-1 drugs
A new proposal by the Biden administration would see obesity drugs covered under Medicare and Medicaid. Transcript: Conway Gittens: The Dow and the S&P 500 closed at fresh record highs on Tuesday as investors tried to pick winners and losers...
Eli Lilly, Novo Nordisk Stocks Gain as Biden Moves to Expand Coverage of Weight-Loss Drugs
Eli Lilly (LLY) and Novo Nordisk (NVO) shares rose Tuesday after the Biden administration proposed expanding coverage of the companies' popular weight-loss drugs in government-backed healthcare plans including Medicare and Medicaid.
Obesity drugmaker stocks gain as Biden proposal expands coverage for anti-obesity medications
Shares of obesity drugmakers moved higher on Tuesday after the Biden administration proposed expanded coverage of anti-obesity medications under Medicare and Medicaid. Currently, these programs cover the use of anti-obesity medications for certain conditions like diabetes, but under the proposal,...
Biden administration plans to expand coverage of GLP-1 drugs for Americans with Medicare & Medicaid
CNBC's Bertha Coombs joins 'Squawk on the Street' to report on Biden's administration plan to expand coverage of GLP-1 drugs for Americans with Medicare and Medicaid.
Novo Nordisk shares rise as Biden proposes obesity care coverage
Shares of Danish weight-loss drug maker Novo Nordisk rose 1.3% on Tuesday as U.S. President Jo Biden proposed expanding coverage of anti-obesity drugs for millions on Medicare and Medicaid.
Source: https://incomestatements.info
Category: Stock Reports